title: Should academic therapeutic patents go to the highest bidder?
abstract: Universities conduct biomedical research with the self-stated goal of disseminating the benefits to the global public. Licensing therapeutic patents to the highest bidder is counterproductive to this aim, as it prioritizes income maximization over dissemination. We believe that licensing strategies focused on promoting broad access to university-discovered therapeutics better serve both the mission of universities and the public good.
authors.affiliation: Universities Allied for Essential Medicines (UAEM), Sarah Lawrence College , 434 E 10th St #4, NY 10009 , USA +1 646 450 0752 ; +1 866 690 1178 ; bcollinsworth@uaem.org.
authors.forename: Bryan
authors.initials: B
authors.lastname: Collinsworth
authors.forename: Sara E
authors.initials: SE
authors.lastname: Crager
mesh_terms: D000046:Academic Medical Centers / Q000191:economics* / Q000941:ethics; D035843:Biomedical Research; D006801:Humans; D008004:Licensure; D010330:Patents as Topic; D010361:Patients; D035842:Research Subjects; D014495:Universities